<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166576">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02020798</url>
  </required_header>
  <id_info>
    <org_study_id>PEP-1328</org_study_id>
    <nct_id>NCT02020798</nct_id>
  </id_info>
  <brief_title>Glycemic Response Testing</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>PepsiCo Global R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glycemic Index Laboratories, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PepsiCo Global R&amp;D</source>
  <oversight_info>
    <authority>Canada: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether food ingredient(s) affect glycemic responses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Incremental area under the blood glucose response curve</measure>
    <time_frame>0-2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Glycemic response calculated from individual glucose measurements upon consumption of control and experimental test food products. The individual glucose measurements will be collected at baseline (prior to consumption of each test food product) and over a 2-hour period following the initiation of consumption of each test food product. The primary outcome is differential treatment-effect on the time-concentration glucose curve over the 2 hours post consumption of each test food product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of decline in blood glucose, peak blood glucose, peak insulin and adjusted time concentration area for insulin</measure>
    <time_frame>0-2 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Glycemic Response</condition>
  <arm_group>
    <arm_group_label>Nutrient formulations without active ingredient</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 nutrient formulations without active ingredient and variable level of available placebo ingredient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nutrient formulation with active ingredien</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 nutrient formulations with increasing amount of active ingredient</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dietary Intervention</intervention_name>
    <arm_group_label>Nutrient formulation with active ingredien</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is 18-75 years of age

          -  Subject has a body mass index (BMI) ≥ 20.0 and &lt; 35 kg/m² at screening (visit 1).

          -  Subject has normal fasting serum glucose (&lt;7.0mmol/L capillary corresponding to whole
             blood glucose &lt;6.3mmol/L).

          -  Subject has no health conditions that would prevent him from fulfilling the study
             requirements as judged by the Investigator on the basis of medical history.

          -  Subject understands the study procedures and signs forms providing informed consent
             to participate in the study and authorization for release of relevant protected
             health information to the study investigator.

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Campbell</last_name>
      <phone>+1 416-861-0506</phone>
    </contact>
    <investigator>
      <last_name>Tomas Wolever, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 19, 2013</lastchanged_date>
  <firstreceived_date>December 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
